Study Phase 3

A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension

Trial Information

Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaBehaviors and Mental DisordersEnrollment363% Female53%% White92%
Product ClassAnticonvulsantsSponsor Protocol NumberTOPMAT-PDMD-005 (CR002248)Data PartnerJohnson & JohnsonCondition StudiedBipolar DisorderMean/Median Age (Years)43

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.